Alkem Laboratories Announces Key Corporate Dates
Alkem Laboratories (BSE: ALKEM), a prominent Indian pharmaceutical company, has announced important upcoming dates related to shareholder returns. The Board of Directors at its recent meeting fixed August 7 as the record date for payment of the final dividend to eligible shareholders.
Additionally, the board set August 20 as the cut-off date for shareholders to be eligible to participate in the Annual General Meeting. These dates align with standard corporate governance practices for dividend distribution and AGM attendance.
Record Date Significance
The record date of August 7 serves as the eligibility cut-off for shareholders entitled to receive the final dividend. Investors holding shares in their demat account by this date will qualify for the dividend payout. The exact dividend amount and payout date would be communicated separately through official exchanges.
Shareholders are advised to ensure their shareholding details are updated with their respective depositories and registrars before the record date to avoid any discrepancy in dividend credit.
AGM Cut-Off Date
The August 20 cut-off date determines which shareholders will receive the AGM notice and be eligible to vote on resolutions tabled at the meeting. Eligible shareholders can expect to receive formal communication regarding the AGM schedule, agenda items, and participation modalities closer to the event date.
About Alkem Laboratories
Alkem Laboratories manufactures and markets a broad range of pharmaceutical formulations and active pharmaceutical ingredients. The company operates across multiple therapeutic segments including anti-infective, gastrointestinal, dermatology, and cardiovascular drugs, serving both domestic and international markets.
This disclosure was made via BSE filing today. Investors and shareholders are encouraged to monitor official exchange communications for any updates regarding dividend amount and AGM proceedings.
Disclaimer: This article is for informational purposes only and does not constitute financial or investment advice. Investors are advised to exercise their own discretion and consult qualified professionals before making investment decisions.